Articles

Find an Article

Filter articles

Applied Filters

Showing 1 to 10 of 33 results

Generic competition: when one door closes, another opens

EU, US26-10-2018

With several major drugs set to face generic or biosimilar competition as patent protection expires, LSIPR analyses how well prepared their manufacturers are and how badly their sales may be affected.

Samsung and HP: here come the techies

International, US15-10-2018

Samsung and HP are just two technology companies that have diversified and invested in the life sciences industry. What impact will this type of activity have on the sector and will it be beneficial in the long run? LSIPR finds out.

3Scan’s Nada Rastad: crossing the line and patenting robotics

US24-09-2018

American biotech 3Scan is combining robotics with machine learning and automation to offer microscopy services for the 3D analysis of cells, tissues, and organs. LSIPR met general counsel Nada Rastad to hear about some of the patenting challenges.

LSIPR 50 2018: Craig Muir

US23-08-2018

Craig Muir was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the investment section, as LSIPR reports.

LSIPR 50 2018: Naoko Munakata

Japan30-07-2018

Naoko Munakata was selected in the LSIPR 50 2018 publication for​ ​her influence on the life sciences industry. She featured in the government and policy section, as LSIPR reports.

LSIPR 50 2018: Raymond Chen and Kathleen O’Malley

US20-07-2018

Raymond Chen and Kathleen O’Malley were selected in the LSIPR 50 2018 publication for​ ​their influence on the life sciences industry. They featured in the government and policy section, as LSIPR reports.

LSIPR 50 2018: Backing the innovators

US17-07-2018

Josh Makower, partner at venture capital investor New Enterprise Associates, explains to LSIPR the firm’s role in supporting medtech innovation, his sweet spot when it comes to projects, and how to balance what is medically relevant with commercial viability.

LSIPR 50 2018: At the head of an experiment in innovation

France09-07-2018

Marie-Paule Kieny of the Drugs for Neglected Diseases Initiative is on a mission to remind stakeholders and governments that there is a moral imperative to pursue the fight against neglected diseases, as she tells LSIPR.

Medicines regulation after Brexit: compromise the key

EU04-06-2018

With Brexit looming, questions are being asked about the future regulatory relationship between the EU and the UK, with life sciences companies wondering how they will be affected. LSIPR reports.

LSIPR 50 2017: Leda Trivinos—Playing the long game

US10-11-2017

Thinking about how IP can assist a company long before it has fully developed is essential, says Leda Trivinos of Flagship Pioneering in an interview with LSIPR.

Showing 1 to 10 of 33 results

LSIPR